A prospective study of the usefulness of circulating tumor DNA (ctDNA) as biomarker for the pancreatic cancer

A prospective study of the usefulness of circulating tumor DNA (ctDNA) as biomarker for the pancreatic cancer - A prospective study of the usefulness of circulating tumor DNA (ctDNA) as biomarker for the pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041261

Enrollment

Registered

2020-07-30

Start date

2020-04-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients are planned to treat according to our protocol for the treatment of pancreatic cancer.

Exclusion criteria

Exclusion criteria: The patients follow our standard treatment protocol of pancreatic cancer.

Design outcomes

Primary

Measure	Time frame
The correlation of the dose of ctDNA during treatment and the survival.	—

Countries

Japan

Contacts

Public ContactYuji Kitahata

2nd department of surgery, Wakayama medical university 2nd department of surgery

Yuji-kh@wakayama-med.ac.jp073-441-0613

Outcome results